FDA Approves Dosage of Pancreatic Enzyme Supplement ZENPEP^® for Infants 

June 17, 2011

Aptalis Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new dosage of its pancreatic enzyme replacement therapy ZENPEP^® (pancrelipase) formulated specifically for infants.

Earlier this week the FDA approved an infant-specific dosage of the pancreatic enzyme CREON^®, made by Abbott Laboratories.

The lower-strength capsules allow for a more precise and consistent dose of pancreatic enzyme supplements to be given to infants with cystic fibrosis.  

Read more in the full release from Aptalis.